reviewNature Reviews Drug DiscoveryJul 1, 2010Closed access

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

HHHarald HampelRFRichard FrankKBKarl BroichSTStefan TeipelRKRussell Katz

Goethe University Frankfurt · Federal Institute for Drugs and Medical Devices · +12 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

631
total citations
FWCI
80.65
Percentile
100%
References
139
Citations per year

Authors

14

Topics & keywords

Topics
Keywords
  • Disease
  • Portfolio
  • Medicine
  • Identification (biology)
  • Alzheimer's disease
  • Drug development
  • Intensive care medicine
  • Drug
No related works found for this paper.

Funding